Psychedelics biotech Cybin Inc. (NYSE:CYBN) has received clearance from the Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for CYB004, its novel deuterated DMT molecule for Generalized Anxiety Disorder (GAD) treatment. This will enable the company to initiate a Phase 2a study in Q1 2024.
Ciphers show anxiety disorders are reported among the most prevalent mental health disorders globally and contribute to some 28 million disability-adjusted life years (DALYs). Specifically, GAD is the most common anxiety disorder seen in primary care, with a 12-month prevalence of 2.9% ...